Related Experiment Video

Updated: Sep 8, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Association Between Elevated Lipoprotein(a) and Diastolic Dysfunction: A Retrospective Cohort Study

Hesham Sheashaa1, Kamal Awad1, Arshad Mohammed2

  • 1Department of Cardiovascular Medicine, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA.

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
|July 15, 2025
PubMed

Insights

Elevated Lipoprotein(a) [Lp(a)] was not linked to diastolic dysfunction (DD) in patients with preserved ejection fraction (EF). Traditional cardiovascular risk factors, not Lp(a), were associated with DD.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Clinical Medicine

Background:

  • Lipoprotein(a) [Lp(a)] is implicated in myocardial fibrosis and endothelial dysfunction, potential contributors to diastolic dysfunction (DD).
  • This study investigates the association between elevated Lp(a) levels (≥ 50 mg/dL) and DD in patients with preserved ejection fraction (EF).

Purpose of the Study:

  • To assess the relationship between elevated Lipoprotein(a) and diastolic dysfunction in patients with preserved ejection fraction.
  • To identify factors associated with diastolic dysfunction in this patient population.

Main Methods:

  • Analysis of 1492 adult patients with Lp(a) measurements and echocardiograms.
  • Diastolic dysfunction defined by ≥ 3 abnormal echocardiographic parameters.
  • Logistic regression analysis adjusted for potential confounders.

Main Results:

  • Elevated Lp(a) (≥ 50 mg/dL) was not associated with diastolic dysfunction (aOR: 0.89, 95% CI: 0.49-1.54).
  • Age, hypertension, diabetes mellitus, and pre-existing cardiovascular diseases were significantly associated with DD.
  • Statin therapy showed a reduced risk of DD (aOR: 0.51).

Conclusions:

  • Lipoprotein(a) is not associated with diastolic dysfunction in patients with preserved ejection fraction.
  • Management of traditional cardiovascular risk factors is crucial for addressing diastolic dysfunction in this cohort.
Abstract

Keywords:
CardiovascularCholesterolDiastolic dysfunctionLipoprotein

More Related Videos

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

27.5K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
74
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
32
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
33